Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models

Area of Science:

• Neuro-oncology
• Immunology
• Pharmacology

Background:

• Medulloblastoma and glioblastoma are common primary brain tumors.
• Tumor-associated macrophages/microglia interact with CD24 on tumor cells via Siglec-10, promoting immune evasion.
• The CD24/Siglec-10 axis in brain tumors is understudied.

Purpose of the Study:

• Investigate the role of the CD24/Siglec-10 axis in malignant brain tumors.
• Evaluate mitoxantrone's effect on this axis and anti-tumor immunity.

Main Methods:

• In silico analysis of CD24 gene expression.
• Analysis of Siglec-10 and TREM2 co-expression in human and mouse brain tumors.
• In vitro studies on brain tumor cell cultures treated with mitoxantrone.
• In vivo studies using a murine glioma model treated with intratumoral mitoxantrone.

Main Results:

• CD24 expression correlates with prognosis in medulloblastoma and glioblastoma.
• Siglec-10+ cells co-express TREM2 in brain tumors.
• Mitoxantrone reduced cell viability and CD24 levels in vitro.
• In vivo, mitoxantrone extended survival, reduced tumor size, decreased Siglec-10+/TREM2+ cells, and increased CD8+ cells.

Conclusions:

• Targeting the CD24/Siglec-10 axis with mitoxantrone shows therapeutic potential.
• Mitoxantrone may modulate the tumor microenvironment and boost anti-tumor immunity.